RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+5.59%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$908M
AUM Growth
+$908M
(+6.2%)
Cap. Flow
+$37.5M
Cap. Flow
% of AUM
4.13%
Top 10 Holdings %
Top 10 Hldgs %
29.34%
Holding
100
New
7
Increased
28
Reduced
31
Closed
12
Top Buys
| 1 |
Horizon Bancorp
HBNC
|
$26.2M |
| 2 |
HCA Healthcare
HCA
|
$18.4M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$9.08M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.72M |
| 5 |
STML
Stemline Therapeutics, Inc.
STML
|
$7.57M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$24.8M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
$14.8M |
| 3 |
AGN
Allergan plc
AGN
|
$13M |
| 4 |
Cigna
CI
|
$10M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
$9.17M |
Sector Composition
| 1 | Healthcare | 91.04% |
| 2 | Financials | 2.97% |
| 3 | Industrials | 0.36% |
| 4 | Technology | 0.08% |
| 5 | Energy | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$13.5B
| $15.2M | 1.67% |
180,000
+2,909
| +2% | +$246K |
|
|
27
Cigna
CI
$80.2B
| $15.2M | 1.67% |
96,191
-63,500
| -40% | -$10M |
|
28
MacroGenics
MGNX
$121M
| $14.5M | 1.6% |
857,169
-110,017
| -11% | -$1.87M |
|
|
29
Regeneron Pharmaceuticals
REGN
$59.8B
| $14.1M | 1.55% |
45,014
+29,014
| +181% | +$9.08M |
|
30
Xencor
XNCR
$594M
| $13.1M | 1.44% |
319,792
-6,173
| -2% | -$253K |
|
|
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.3M | 1.36% |
949,833
| – | – |
|
32
Cencora
COR
$57.2B
| $12.1M | 1.33% |
141,520
+25,000
| +21% | +$2.13M |
|
|
IMMU
33
DELISTED
Immunomedics Inc
IMMU
| $11.8M | 1.3% |
851,367
+235,000
| +38% | +$3.26M |
|
|
MYOK
34
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $11.3M | 1.24% |
225,024
| – | – |
|
35
LivaNova
LIVN
$3.09B
| $10.8M | 1.19% |
150,000
-90,600
| -38% | -$6.52M |
|
36
Exact Sciences
EXAS
$9.33B
| $10.6M | 1.17% |
90,000
-10,000
| -10% | -$1.18M |
|
37
Agios Pharmaceuticals
AGIO
$2.36B
| $9.98M | 1.1% |
200,000
+72,988
| +57% | +$3.64M |
|
|
ARNA
38
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $9.97M | 1.1% |
170,000
-64,558
| -28% | -$3.78M |
|
39
Exelixis
EXEL
$9.95B
| $9.83M | 1.08% |
460,000
+30,000
| +7% | +$641K |
|
|
SGEN
40
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.37M | 1.03% |
135,374
-15,224
| -10% | -$1.05M |
|
|
BLUE
41
DELISTED
bluebird bio
BLUE
| $8.9M | 0.98% |
5,404
+1,158
| +27% | +$1.91M |
|
42
Thermo Fisher Scientific
TMO
$183B
| $8.75M | 0.96% |
29,800
-200
| -0.7% | -$58.7K |
|
43
Omnicell
OMCL
$1.51B
| $8.64M | 0.95% |
100,375
| – | – |
|
44
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $8.62M | 0.95% |
390,000
-61,131
| -14% | -$1.35M |
|
45
Sangamo Therapeutics
SGMO
$161M
| $8.55M | 0.94% |
793,957
-50,000
| -6% | -$539K |
|
46
Incyte
INCY
$17B
| $8.5M | 0.94% |
100,000
| – | – |
|
|
GTHX
47
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $8.41M | 0.93% |
274,274
+62,105
| +29% | +$1.9M |
|
|
AERI
48
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $7.68M | 0.85% |
260,000
| – | – |
|
|
STML
49
DELISTED
Stemline Therapeutics, Inc.
STML
| $7.57M | 0.83% |
+493,999
| New | +$7.57M |
|
|
DPLO
50
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $7.33M | 0.81% |
1,203,405
| – | – |
|